EMERYVILLE, Calif., November 1, 2023 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced two poster presentations: one on the company’s lead mRNA therapeutic candidate, NTX-250, which targets human papillomavirus (HPV)-driven cancers; the other on its latest therapeutic candidate, NTX-471, which targets CD47 and […]
EMERYVILLE, Calif. — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the appointment of Cynthia Collins, to the company’s board of directors. Collins joins Nutcracker Therapeutics with more than four decades of experience working in the pharmaceutical and biotech industry. She currently is the […]
EMERYVILLE, Calif., May 2, 2023 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, will present at this year’s TIDES USA, or the Oligonucleotide and Peptide Therapeutics conference, being held May 7-10, 2023 in San Diego, CA. Nutcracker Therapeutics has developed its Nutshell™ platform of peptoid […]
Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting
April 19, 2023
EMERYVILLE, Calif., April 19, 2023 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April […]
Nutcracker Therapeutics Announces Two Preclinical Data Presentations for Lead mRNA Candidate, NTX-250, at the 2023 AACR Annual Meeting
March 28, 2023
EMERYVILLE, Calif., March 27, 2023 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, will present two posters outlining new preclinical data for its lead therapeutic candidate, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, Fla., from April […]
Nutcracker Therapeutics Appoints Industry Veteran Angela Peters as Chief Human Resources Officer
March 7, 2023
EMERYVILLE, Calif., March 7, 2023 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the appointment of Angela Peters as the company’s first Chief Human Resources Officer (CHRO). Peters joins the company amidst an ongoing strengthening of the company’s therapeutic efforts, which included the appointment […]
EMERYVILLE, Calif. — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the appointment of Thomas J. Dietz, Ph.D., to the company’s board of directors. Dr. Dietz brings to Nutcracker Therapeutics nearly three decades of experience in the investment banking and pharmaceutical industries. He is […]
Nutcracker Therapeutics Reports Strong Anti-Tumor Responses of Lead mRNA Immunotherapy in Preclinical Data Presented at SITC Annual Meeting 2022
November 11, 2022
EMERYVILLE, Calif. — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting. The data demonstrate that NTX-250 has the ability to elicit […]
Nutcracker Therapeutics to Present Data for Lead Candidate at 2022 SITC Annual Meeting
October 13, 2022
EMERYVILLE, Calif. — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the upcoming poster presentation of new preclinical data for its lead therapeutic candidate, NTX-0250, which targets human papillomavirus (HPV)-driven cancers. The company will present this data at the 37th annual meeting of the […]
For inquiries, please visit our Contact Page.
